News

GEN - Genetic Engineering and Biotechnology News2d
Insilico Eyes Q4 Start for Late-Stage Trials of IPF Candidate
Insilico plans late-stage trials for rentosertib following positive mid-stage safety and efficacy data for idiopathic ...
News Medical3mon
AI-driven discovery unveils TNIK inhibition as anti-aging strategy
Qiuqiong Tang, PhD, biologist at Insilico Medicine and first author of the paper Previous studies have shown that TNIK (Traf2- and Nck-interacting kinase) plays an essential role in the cellular ...
Yahoo Finance8mon
Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AI
ISM001-055 is a novel drug designed in-house using generative AI to target TNIK (Traf2- and NCK- interacting kinase) and has progressed through Phase IIa clinical testing. Preliminary results from ...
BioSpace8mon
Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AI
ISM001-055 is a novel drug designed in-house using generative AI to target TNIK (Traf2- and NCK- interacting kinase) and has progressed through Phase IIa clinical testing. Preliminary results from ...
ahajournals.org2y
Proteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-Cardiomyopathy
The E3 ubiquitin ligase TRAF2 (TNF receptor associated factor 2) provides a critical signaling platform for K63-linked polyubiquitination of RIPK1 (receptor interacting protein 1), crucial for nuclear ...
Frontiers3y
N4BP3 Regulates RIG-I-Like Receptor Antiviral Signaling Positively by Targeting Mitochondrial Antiviral Signaling Protein
We also detected that N4BP3 could accelerate the interaction between MAVS and TRAF2. Related experiments revealed that N4BP3 could facilitate the ubiquitination modification of MAVS. These findings ...